<DOC>
	<DOCNO>NCT02303028</DOCNO>
	<brief_summary>This phase I , dose escalation study topotecan administer low dos give frequently prolong schedule ( low dose metronomic ; LDM ) , combination fix dose pazopanib . The maximum tolerated dose ( MTD ) recommend phase 2 dose ( RP2D ) evaluate LDM topotecan combination pazopanib child recurrent refractory solid tumour include CNS tumour . Pharmacokinetic pharmacodynamic study conduct define exposure activity LDM topotecan combination pazopanib .</brief_summary>
	<brief_title>Phase I Dose Escalation Study Topotecan Pazopanib Children With Recurrent/Refractory Solid CNS Tumours</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>INCLUSION : 1 . Disease : Part 1Relapsed refractory solid tumour include CNS tumour ; Part 2ANeuroblastoma , Part 2B Rhabdomyosarcoma 2 . Measurable evaluable disease 3 . No known curative therapy , therapy proven prolong survival acceptable QOL 4 . Organ Function Criteria Peripheral ANC ≥ 1,500/μL ; Plt ≥ 100,000/ Hb ≥ 80 g/L ( RBC transfusion permit ) Measured creatinine clearance radioisotope GFR ≥ 70 mL/min/1.73 m2 , OR serum creatinine base age/gender meet criteria outline protocol Urinalysis negative protein , urine protein : creatinine ratio ≤ 1 , OR 24hour urine protein &lt; 1000 mg/dL &lt; Gr.1 abnormality K , Ca ( confirm ionize Ca ) , Mg Ph ( supplementation allow ) Total serum bilirubin ≤ 1.5xULN age SGPT ( ALT ) ≤ 2.5 x ULN SGOT ( AST ) ≤ 2.5 x ULN Serum albumin ≥ 20 g/L Adequate systolic ventricular function ( LVSF≥ 27 % LVEF ≥ 50 % ) QTc measure ECG must &lt; 450 msec . No history MI , severe unstable angina , peripheral vascular disease , familial QTc prolongation Blood pressure ≤ 95th percentile age , height , gender AND one : No current antihypertensive therapy , OR stable dos one antihypertensive medication Subjects know history seizure must wellcontrolled seizure receive enzymeinducing anticonvulsant INR ≤ 1.2 PTT ≤ 1.2xULN 5 . Prior Therapy Myelosuppressive chemo must give within 3 week study enrolment ( 6 week nitrosourea ) At least 7 day must elapse since completion therapy growth factor support platelet white cell number function . At least 14 day must elapse receive pegfilgrastim . Biologic antineoplastic agent ( include VEGFblocking TKI ) must administer within 7 day study enrolment At least 3 half life monoclonal antibody must elapse since last dose administer ≥ 2 week must elapse since local palliative XRT ( small port ) ; &gt; 13 week since prior total body irradiation ( TBI ) , craniospinal XRT &gt; 50 % radiation pelvis ; &gt; 6 week substantial bone marrow irradiation ≥ 8 week must elapse since MIBG therapy neuroblastoma At least 60 day must elapse autologous allogeneic stem cell transplant sign GVHD . At least 28 day major surgery wound must heal . At least 7 day open and/or core biopsy . 6 . Ability take liquid medication mouth EXCLUSION : 1 . Patients DIPG , know CNS metastases 2 . Pregnancy , breast feeding , unwillingness use effective contraception study 3 . Subjects currently receive : Corticosteroids n't stable decrease dose corticosteroid 7 day prior Another investigational drug ; anticancer agent radiation therapy More one medication blood pressure control Therapeutic anticoagulation , include systemic use warfarin , heparin , low molecular weight heparin dose Aspirin , and/or ibuprofen , NSAIDs Drugs metabolize several specific P450 cytochrome isoforms receive drug know risk torsades de pointes Subjects require thyroid replacement therapy eligible receive stable replacement dose least 4 week prior study enrolment . 4 . Subjects uncontrolled infection serious nonhealing would , ulcer bone fracture . 5 . Evidence active bleeding , intratumoral haemorrhage , bleed diathesis , hemoptysis evidence GI hemorrhage . 6 . Major surgical procedure , laparoscopic procedure significant traumatic injury within 28 day prior Day 1 therapy . Open core biopsy within 7 day prior Day 1 therapy . 7 . Previous , documented hypersensitivity reaction topotecan pazopanib 8 . History abdominal fistula , GI perforation , intraabdominal abscess within 28 day study enrolment .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Pediatric</keyword>
	<keyword>CNS Tumor</keyword>
	<keyword>Solid Tumour</keyword>
</DOC>